|
|
|
|
|
À¯·áȸ¿ø °áÀç½Ã¿¡´Â º¸´Ù ´Ù¾çÇÑ ¾à¹°Á¤º¸¸¦
ÀÌ¿ëÇÏ½Ç ¼ö ÀÖ½À´Ï´Ù.
À¯·áÁ¤º¸¸ñ·ÏÀº Àü¹®È¸¿øÀ¸·Î
·Î±×ÀÎ ÇϽøé È®ÀÎ °¡´ÉÇÕ´Ï´Ù.
|
|
|
 | Çã°¡Á¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
û±¸ÄÚµå(KDÄÚµå) ºñ±Þ¿©Á¡°ËÄÚµå »óÇÑ±Ý¾× |
ºñ±Þ¿©
[»óº´ÄÚµåÁ¶È¸]
[Áúº´ÄÚµåÁ¶È¸]
|
| ºü¸¥Á¶È¸ |
|
| Á¦Ç°¼º»ó |
ü¸®ÇâÀ» °®´Â ¹ÌȲ»öÀÇ Åõ¸íÇÑ ¾×ü [Á¦ÇüÁ¤º¸ È®ÀÎ] |
| È¿´ÉÈ¿°ú |
[ÀûÀÀÁõ º° °Ë»ö]
È¿´É.È¿°ú
(¾×Á¦)
ºñŸ¹Î ¹× öºÐÀÇ º¸±Þ, ÃæÄ¡¿¹¹æÀ» À§ÇÑ ºÒ¼ÒÀÇ º¸±Þ
|
| ¿ë¹ý¿ë·® |
* Àý´ë ÀÓÀǺ¹¿ëÇÏÁö ¸¶½Ã°í ¹Ýµå½Ã ÀÇ»ç ¶Ç´Â ¾à»ç¿Í »ó´ãÇϽñ⠹ٶø´Ï´Ù.
[󹿾à¾î]
¿ë¹ý.¿ë·®
(¾×Á¦)
»ó¼öµµ¿¡ºÒ¼Ò¸¦ 0.3 ppm ¹Ì¸¸À¸·Î ÇÔÀ¯Çϰí ÀÖ´Â Áö¿ªÀÇ 3°³¿ù¢¦2¼¼ ÀÌÇÏÀÇ ¿µ¾Æ¿¡°Ô 1ÀÏ 1 mL¾¿Á÷Á¢ °æ±¸Åõ¿©Çϰųª °úÀÏÁÖ½º µîÀÇ À½½Ä¹°°ú È¥ÇÕÇÏ¿© Åõ¿©ÇÑ´Ù.
|
| ÷°¡Á¦ ÁÖÀÇ»çÇ× |
* ÷°¡Á¦ ÁÖÀÇ»çÇ×Á¤º¸´Â ÇöÀç ¾÷µ¥ÀÌÆ®ÁßÀÌ¸ç ¹Ì¾÷µ¥ÀÌÆ®µÈ ÀǾàǰÀÇ Ã·°¡Á¦
ÁÖÀÇ»çÇ×Àº Ç¥½ÃµÇÁö ¾ÊÀ»¼ö ÀÖ½À´Ï´Ù.
¾È½ÄÇâ»ê³ªÆ®·ý (º¯°æÁö½Ã Àǰü 65623-601, 2001. 3. 12.)
¡Û ÀϹÝÀû ÁÖÀÇ
ÀÌ ¾àÀº ¾È½ÄÇâ»ê³ªÆ®·ýÀ» Æ÷ÇÔÇϰí ÀÖÀ¸¸ç, ¾È½ÄÇâ»êÀº ÇǺÎ, ´«, Á¡¸·¿¡°æ¹ÌÇÑ ÀÚ±ØÀÌ µÉ ¼ö ÀÖ´Ù.
Ä«¶ó¸á (°æ±¸Á¦¿¡ ÇÑÇÔ.)
¡Û ´ÙÀ½ ȯÀÚ¿¡´Â ½ÅÁßÈ÷ Åõ¿©ÇÒ °Í.
ÀÌ ¾àÀº Ä«¶ó¸áÀ» ÇÔÀ¯Çϰí ÀÖÀ¸¹Ç·Î ÀÌ ¼ººÐ¿¡ °ú¹ÎÇϰųª¾Ë·¹¸£±â º´·ÂÀÌ Àִ ȯÀÚ¿¡´Â ½ÅÁßÈ÷ Åõ¿©ÇÑ´Ù.
|
| ±Ý±â |
1) ÀÌ ¾à ¹× ÀÌ ¾à¿¡ Æ÷ÇÔµÈ ¼ººÐ¿¡ÀÇ °ú¹Î¹ÝÀÀ ȯÀÚ
2) °íÄ®½·Ç÷Áõ(hypercalcemia : Ç÷¾×Áß¿¡ Ä®½·À̰úÀ×À¸·Î Á¸ÀçÇÏ´Â »óÅÂ) ȯÀÚ, À¯À°Á¾Áõ(sarcoidosis), ½ÅÁúȯ ȯÀÚ
3) Ç÷»ö¼ÒÁõ(ö´ë»ç ÀÌ»óÀ¸·Î öÀÌ °£Àå, ÃéÀå¿¡ Ä§ÂøÇÏ´Â Áúȯ), Çì¸ð½Ãµ¥¸°Ä§ÂøÁõ, ºñö°áÇ̼º ºóÇ÷
|
| ½ÅÁßÅõ¿© |
1) 12°³¿ù ¹Ì¸¸ÀÇ ¿µ¾Æ
2) ÀÇ»çÀÇ Ä¡·á¸¦ ¹Þ°í Àִ ȯÀÚ
3) ÇÞºûÀ» ¸¹ÀÌ º¸°í Á¤»óÀûÀÎ ½Ä»ç¸¦ ÇÏ´Â ¾î¸°ÀÌ¿¡°Ô´Â ºñŸ¹Î D¶Ç´Â Ä®½·ÀÇ Åõ¿©¸¦ ÇÇÇÒ °Í.
4) °í¼ö»ê´¢Áõ(hyperoxaluria : ¿äÁß¿¡ °ú·®ÀÇ ¼ö»ê¿°ÀÌ ¹è¼³µÇ´Â»óÅÂ) ȯÀÚ
5) ½ÉÀ塤¼øÈ¯±â°è±â´É Àå¾Ö, ½ÅÀå¾Ö, Àú´Ü¹éÇ÷ÁõȯÀÚ
6) ¼Òȼº±Ë¾ç, ¸¸¼º±Ë¾ç¼º´ëÀå¿°, ±¹ÇѼº´ëÀå¿°µîÀÇ À§ÀåÁúȯ ȯÀÚ
7) Ç׾˵µ½ºÅ×·ÐÁ¦, Æ®¸®¾ÏÅ×·»À» º¹¿ë ÁßÀΠȯÀÚ(°íÄ®·ýÇ÷ÁõÀ» ÀÏÀ¸Å³ ¼ö ÀÖÀ¸¹Ç·Î ÁÖÀÇÇÒ °Í.)
|
| ÀÌ»ó¹ÝÀÀ |
1) ±¸¿ª, ±¸Åä, ¼³»ç, À§ºÎºÒÄè°¨, º¯ºñ, ¹±Àºº¯, ½Ä¿åºÎÁø, À§ºÎÆØ¸¸°¨,º¹ºÎÆØ¸¸°¨, º¹ºÎ¡¤À§ÅëÁõ, À§°æ·Ã
2) °¡·Á¿ò, ¹ßÁø(¾Ë·¹¸£±â¼ºÆ÷ÇÔ), ¹ßÀû, °ÇÁ¶ÇÏ°í °ÅÄ£ÇǺÎ, ¾ó±¼¡¤´Ù¸® Á¾Ã¢, µÎµå·¯±â, ±¤¼±°ú¹ÎÁõ
3) ¾îÁö·¯¿ò, ¿, È¥¼ö
4) ÅëÁõ¼º °üÀýºÎÁ¾
5) ƯÀÌüÁúÁõ»ó
6) °í¿ë·® Åõ¿©¿¡ ÀÇÇÑ ¼Òȼº±Ë¾çÀÇ ÃËÁø, ´ç³»¼º ¼Õ»ó(glucose tolerance impairment : ½ÅüÀÇ Æ÷µµ´çÀ» ´ë»çÇÏ´Â ´É·Â Àå¾Ö), °í¿ä»êÇ÷Áõ(hyperuricemia : Ç÷¾×Áß¿¡ ¿ä»êÀÌ °úÀ×À¸·ÎÁ¸ÀçÇÏ´Â »óÅÂ), °£¼Õ»ó ¹ß»ý
7) Àå±â°£ °í¿ë·® Åõ¿©¿¡ ÀÇÇÑ ³»¼º ¹ßÇö
8) ÇǸ®µ¶½ÅÀ» 1ÀÏ50 §·¢¦2 gÀÇ ¿ë·®À¸·Î Àå±â°£ º¹¿ëÇÏ¸é °¨°¢½Å°æº´ ¶Ç´Â ½Å°æº´Áõ(neuropathy : ¸»ÃʽŰæ°èÀÇ ±â´ÉÀû Àå¾Ö ¶Ç´Â º´Àûº¯È)À̳ªÅ¸³¯ ¼ö ÀÖ´Ù.
9) ´ë·®Åõ¿©·Î ÀÎÇÑ ±¸¿ª, ±¸Åä µîÀÇ À§ÀåÁõ»ó, °í³ªÆ®·ýÇ÷Áõ, ¿ïÇ÷¼º½ÉºÎÀü, ºÎÁ¾µîÀÇ Áõ»ó
|
| »óÈ£ÀÛ¿ë |
1) Àλ꿰, Ä®½·¿°, °æ±¸¿ë Åׯ®¶ó»çÀÌŬ¸°°èÁ¦Á¦, Á¦»êÁ¦
2) ·¹º¸µµÆÄ
|
| Off-label Usage |
[Á¶È¸]
|
| Related FDA Approved Drug |
±âÁØ ¼ººÐ: CHOLECALCIFEROLCERNEVIT-12 (ALPHA-TOCOPHEROL; ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; FOLIC ACID; NIACINAMIDE; PANTOTHENIC ACID; PYRIDOXINE; RIBOFLAVIN; THIAMINE; VITAMIN A)
FOSAMAX PLUS D (ALENDRONATE SODIUM; CHOLECALCIFEROL)
INFUVITE ADULT (ALPHA-TOCOPHEROL ACETATE; ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A PALMITATE; VITAMIN K)
INFUVITE PEDIATRIC (ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; TOCOPHEROL ACETATE; VITAMIN A; VITAMIN K)
INFUVITE PEDIATRIC (PHARMACY BULK PACKAGE) (ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; TOCOPHEROL ACETATE; VITAMIN A; VITAMIN K)
±âÁØ ¼ººÐ: ASCORBIC ACID 3500MG±âÁØ ¼ººÐ: Ä«¶ó¸á
|
|
|
 | Á¤º¸¿ä¾à |
|
|
|
µå·°ÀÎÆ÷ ÀǾàǰ ¿ä¾à/»ó¼¼Á¤º¸
|
|
 | ÄÚµå ¹× ºÐ·ùÁ¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
| ¼ººÐÄÚµå |
M040064/´ÏÄÚÆ¾»ê¾Æ¹Ìµå 800¹Ð¸®±×·¥ /
M040230/ºÒȳªÆ®·ý 55.25¹Ð¸®±×·¥ /
M040354/¾Æ½ºÄÚ¸£ºó»ê 3500¹Ð¸®±×·¥ /
M040381/¾È½ÄÇâ»ê³ªÆ®·ý /
M040512/Àλ긮º¸Çöóºó³ªÆ®·ý 60¹Ð¸®±×·¥ /
M040558/¿°»êÄ¡¾Æ¹Î 50¹Ð¸®±×·¥ /
M040594/ÄÝ·¹Ä®½ÃÆä·Ñ 40000 /
M040751/¿°»êÇǸ®µ¶½Å 40¹Ð¸®±×·¥ /
M040804/Ȳ»êö 4978¹Ð¸®±×·¥ /
M060260/Ä«¶ó¸á /
M090847/ºñŸ¹ÎE 500¾ÆÀÌ.À¯ /
M095773/ºñŸ¹ÎA 150000¾ÆÀÌ.À¯ /
|
| BIT ¾àÈ¿ºÐ·ù |
Á¾ÇÕºñŸ¹Î/¹Ì³×¶ö (Multivitamins / with Minerals)
|
| ATC ÄÚµå |
Multivitamins and iron / A11AA01
[ÄÚµåºÐ·ù»ó¼¼¼³¸í]
[ATCÄÚµå¿¹Ãø]
|
| º¹ÁöºÎºÐ·ùÄÚµå |
316 (È¥ÇÕºñŸ¹ÎÁ¦(ºñŸ¹ÎADÈ¥ÇÕÁ¦Á¦¸¦ Á¦¿Ü) )
|
| Drugs By Indication |
[Àüüº¸±â]
|
| Drugs By Classification |
[Àüüº¸±â]
|
|
|
 | Á¦Ç°Á¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
û±¸ÄÚµå(KDÄÚµå) ºñ±Þ¿©Á¡°ËÄÚµå »óÇÑ±Ý¾× |
ºñ±Þ¿©
[»óº´ÄÚµåÁ¶È¸]
[Áúº´ÄÚµåÁý ´Ù¿î·Îµå]
|
| Á¦Ç°¼º»ó |
ü¸®ÇâÀ» °®´Â ¹ÌȲ»öÀÇ Åõ¸íÇÑ ¾×ü
[Á¦ÇüÁ¤º¸ È®ÀÎ]
|
| ÷°¡Á¦ ÁÖÀÇ»çÇ× |
* ÷°¡Á¦ ÁÖÀÇ»çÇ×Á¤º¸´Â ÇöÀç ¾÷µ¥ÀÌÆ®ÁßÀÌ¸ç ¹Ì¾÷µ¥ÀÌÆ®µÈ ÀǾàǰÀÇ Ã·°¡Á¦
ÁÖÀÇ»çÇ×Àº Ç¥½ÃµÇÁö ¾ÊÀ»¼ö ÀÖ½À´Ï´Ù.
¾È½ÄÇâ»ê³ªÆ®·ý (º¯°æÁö½Ã Àǰü 65623-601, 2001. 3. 12.)
¡Û ÀϹÝÀû ÁÖÀÇ
ÀÌ ¾àÀº ¾È½ÄÇâ»ê³ªÆ®·ýÀ» Æ÷ÇÔÇϰí ÀÖÀ¸¸ç, ¾È½ÄÇâ»êÀº ÇǺÎ, ´«, Á¡¸·¿¡°æ¹ÌÇÑ ÀÚ±ØÀÌ µÉ ¼ö ÀÖ´Ù.
Ä«¶ó¸á (°æ±¸Á¦¿¡ ÇÑÇÔ.)
¡Û ´ÙÀ½ ȯÀÚ¿¡´Â ½ÅÁßÈ÷ Åõ¿©ÇÒ °Í.
ÀÌ ¾àÀº Ä«¶ó¸áÀ» ÇÔÀ¯Çϰí ÀÖÀ¸¹Ç·Î ÀÌ ¼ººÐ¿¡ °ú¹ÎÇϰųª¾Ë·¹¸£±â º´·ÂÀÌ Àִ ȯÀÚ¿¡´Â ½ÅÁßÈ÷ Åõ¿©ÇÑ´Ù.
|
|
|
 | º¹¾àÁ¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
| LACTmed ¹Ù·Î°¡±â |
[¹Ù·Î°¡±â]
|
| ¾à¸®ÀÛ¿ë |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| º¹¾àÁöµµ |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| ÀӺο¡´ëÇÑÅõ¿© |
| * |
ÀüüÀӽŠ±â°£º°·Î ¿©·¯µî±ÞÀÌ Á¸ÀçÇÒ ¼ö ÀÖÀ¸¸ç °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ º¸¿©Áý´Ï´Ù. ´Ü, º¹ÇÕÁ¦ÀÇ °æ¿ì ¸ðµç º¹ÇÕÁ¦¼ººÐ¿¡ ´ëÇÑ ÀÓºÎÅõ¿©µî±ÞÀÌ Ç¥½ÃµÈ°ÍÀº Àý´ë ¾Æ´Ï¸ç Ç¥½ÃµÈ°ÍÁß¿¡ °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ ³ªÅ¸³³´Ï´Ù.
|
|
|   |
 FDA : Cµî±Þ
(fluoride; )
|
|
| * |
»ó±â ÀÓºÎÅõ¿©¿¡ ´ëÇÑ Á¤º¸´Â Àü»êó¸® µÇ¸é¼ ÀÔ·Â ¿À·ù °¡´É¼ºÀÌ Á¸ÀçÇÕ´Ï´Ù. ¿À·ù °¡´É¼ºÀ» ÃÖ¼ÒÈÇϱâ À§ÇÏ¿© ¸¹Àº ³ë·ÂÀ» ±â¿ïÀ̰í ÀÖÀ¸³ª, ±× Á¤È®¼º¿¡ ´ëÇÏ¿© È®½ÅÀ» µå¸± ¼ö ¾ø½À´Ï´Ù. ÀÌ¿¡ ´ëÇØ ȸ»ç´Â Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù.
|
| * |
¹Ýµå½Ã °ø½Å·Â ÀÖ´Â ¹®ÇåÀ» ´Ù½Ã Çѹø Âü°í ÇϽñ⠹ٶó¸ç ÀÇ»ç ¶Ç´Â ¾à»çÀÇ ÆÇ´Ü¿¡ µû¶ó Åõ¿©¿©ºÎ°¡ °áÁ¤µÇ¾î¾ß ÇÕ´Ï´Ù.
|
|
|
| º´¿ë±Ý±â ¹× ¿¬·É´ë±Ý±â ±Ù°ÅÁ¶È¸ |
[º´¿ë±Ý±â ¹× ¿¬·É´ë±Ý±â ±Ù°ÅÁ¶È¸]
|
| º¹¾à¶óº§ |
| À̹ÌÁö |
º¹¾à¼³¸í |
 |
º¯ºñ°¡ »ý±æ¼ö ÀÖ½À´Ï´Ù. |
|
 |
¾îÁö·¯¿òÀÌ ÀÖÀ»¼ö ÀÖ½À´Ï´Ù. |
|
|
| * |
º¹¾àÀ̹ÌÁö´Â ¸ðµç º¹¾àÁöµµ »çÇ×À» Ç¥½ÃÇѰÍÀº ¾Æ´Ï¸ç, Ãß°¡ÀûÀ¸·Î ¾÷µ¥ÀÌÆ®µÇ°Å³ª ¼öÁ¤µÉ ¼ö ÀÖ½À´Ï´Ù. |
| * |
º¹¾àÀ̹ÌÁöÀÇ Ç¥½Ã¿©ºÎ´Â ½ÇÁ¦ ¾à¹°º¹¿ë½Ã Á߿䵵¿¡ µû¸¥°ÍÀº ¾Æ´Ï¸ç ´Ü¼øÈ÷ Çã°¡Á¤º¸»ó Ű¿öµå¸¦ ±âÁØÀ¸·Î µî·ÏµÇ¾ú½À´Ï´Ù. |
| * |
±ÍÇϰ¡ º¹¾àÀ̹ÌÁö Á¤º¸¸¦ ½Å·ÚÇÔÀº ÀüÀûÀ¸·Î ±ÍÇÏÀÇ Ã¥ÀÓÀÔ´Ï´Ù. µå·°ÀÎÆ÷´Â ÀÌ¿¡ ´ëÇÑ ¾î¶°ÇÑ º¸Áõµµ ÇÏÁö ¾Ê½À´Ï´Ù. |
|
|
| º¸°ü»ó ÁÖÀÇ |
|
| Á¶Á¦½Ã ÁÖÀÇ |
|
|
|
 | ½É»çÁ¤º¸ |
|
|
|
|
 | ÇмúÁ¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
| DUR (ÀǾàǰ»ç¿ëÆò°¡) |
º´¿ë±Ý±â :
°í½ÃµÈ º´¿ë±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[»óÈ£ÀÛ¿ë/º´¿ë±Ý±â°Ë»ö]
¿¬·É´ë±Ý±â :
°í½ÃµÈ ¿¬·É±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[¿¬·É´ë±Ý±â»ó¼¼°Ë»ö]
|
| µ¶¼ºÁ¤º¸ |
Ascorbic Acid¿¡ ´ëÇÑ µ¶¼ºÁ¤º¸ : Á¤º¸º¸±â
Nicotinamide¿¡ ´ëÇÑ µ¶¼ºÁ¤º¸ : Á¤º¸º¸±â
Pyridoxine¿¡ ´ëÇÑ µ¶¼ºÁ¤º¸ : Á¤º¸º¸±â
Riboflavin¿¡ ´ëÇÑ µ¶¼ºÁ¤º¸ : Á¤º¸º¸±â
Sodium benzoate¿¡ ´ëÇÑ µ¶¼ºÁ¤º¸ : Á¤º¸º¸±â
Vitamin A¿¡ ´ëÇÑ µ¶¼ºÁ¤º¸ : Á¤º¸º¸±â
Ãâó: ±¹¸³µ¶¼º°úÇпø µ¶¼º¹°ÁúÁ¤º¸DB : http://www.nitr.go.kr/nitr/contents/m134200/view.do |
| Mechanism of Action |
Cholecalciferol¿¡ ´ëÇÑ Mechanism_Of_Action Á¤º¸ The first step involved in the activation of vitamin D3 is a 25-hydroxylation which is catalysed by the 25-hydroxylase in the liver and then by other enzymes. The mitochondrial sterol 27-hydroxylase catalyses the first reaction in the oxidation of the side chain of sterol intermediates. The active form of vitamin D3 (calcitriol) binds to intracellular receptors that then function as transcription factors to modulate gene expression. Like the receptors for other steroid hormones and thyroid hormones, the vitamin D receptor has hormone-binding and DNA-binding domains. The vitamin D receptor forms a complex with another intracellular receptor, the retinoid-X receptor, and that heterodimer is what binds to DNA. In most cases studied, the effect is to activate transcription, but situations are also known in which vitamin D suppresses transcription. Calcitriol increases the serum calcium concentrations by: increasing GI absorption of phosphorus and calcium, increasing osteoclastic resorption, and increasing distal renal tubular reabsorption of calcium. Calcitriol appears to promote intestinal absorption of calcium through binding to the vitamin D receptor in the mucosal cytoplasm of the intestine. Subsequently, calcium is absorbed through formation of a calcium-binding protein.
Pyridoxine¿¡ ´ëÇÑ Mechanism_Of_Action Á¤º¸ Vitamin B6 is the collective term for a group of three related compounds, pyridoxine (PN), pyridoxal (PL) and pyridoxamine (PM), and their phosphorylated derivatives, pyridoxine 5'-phosphate (PNP), pyridoxal 5'-phosphate (PLP) and pyridoxamine 5'-phosphate (PMP). Although all six of these compounds should technically be referred to as vitamin B6, the term vitamin B6 is commonly used interchangeably with just one of them, pyridoxine. Vitamin B6, principally in the form of the coenzyme pyridoxal 5'-phosphate, is involved in a wide range of biochemical reactions, including the metabolism of amino acids and glycogen, the synthesis of nucleic acids, hemogloblin, sphingomyelin and other sphingolipids, and the synthesis of the neurotransmitters serotonin, dopamine, norepinephrine and gamma-aminobutyric acid (GABA).
Riboflavin¿¡ ´ëÇÑ Mechanism_Of_Action Á¤º¸ Binds to riboflavin hydrogenase, riboflavin kinase, and riboflavin synthase. Riboflavin is the precursor of flavin mononucleotide (FMN, riboflavin monophosphate) and flavin adenine dinucleotide (FAD). The antioxidant activity of riboflavin is principally derived from its role as a precursor of FAD and the role of this cofactor in the production of the antioxidant reduced glutathione. Reduced glutathione is the cofactor of the selenium-containing glutathione peroxidases among other things. The glutathione peroxidases are major antioxidant enzymes. Reduced glutathione is generated by the FAD-containing enzyme glutathione reductase.
Thiamine¿¡ ´ëÇÑ Mechanism_Of_Action Á¤º¸ It is thought that the mechanism of action of thiamine on endothelial cells is related to a reduction in intracellular protein glycation by redirecting the glycolytic flux.
|
| Pharmacology |
Cholecalciferol¿¡ ´ëÇÑ Pharmacology Á¤º¸ Cholecalciferol (vitamin D3) is a steroid hormone that has long been known for its important role in regulating body levels of calcium and phosphorus, in mineralization of bone, and for the assimilation of Vitamin A. The classical manifestations of vitamin D deficiency is rickets, which is seen in children and results in bony deformaties including bowed long bones. Deficiency in adults leads to the disease osteomalacia. Both rickets and osteomalacia reflect impaired mineralization of newly synthesized bone matrix, and usually result from a combination of inadequate exposure to sunlight and decreased dietary intake of vitamin D. Common causes of vitamin D deficiency include genetic defects in the vitamin D receptor, severe liver or kidney disease, and insufficient exposure to sunlight. Vitamin D plays an important role in maintaining calcium balance and in the regulation of parathyroid hormone (PTH). It promotes renal reabsorption of calcium, increases intestinal absorption of calcium and phosphorus, and increases calcium and phosphorus mobilization from bone to plasma.
Pyridoxine¿¡ ´ëÇÑ Pharmacology Á¤º¸ Vitamin B6 (pyridoxine) is a water-soluble vitamin used in the prophylaxis and treatment of vitamin B6 deficiency and peripheral neuropathy in those receiving isoniazid (isonicotinic acid hydrazide, INH). Vitamin B6 has been found to lower systolic and diastolic blood pressure in a small group of subjects with essential hypertension. Hypertension is another risk factor for atherosclerosis and coronary heart disease. Another study showed pyridoxine hydrochloride to inhibit ADP- or epinephrine-induced platelet aggregation and to lower total cholesterol levels and increase HDL-cholesterol levels, again in a small group of subjects. Vitamin B6, in the form of pyridoxal 5'-phosphate, was found to protect vascular endothelial cells in culture from injury by activated platelets. Endothelial injury and dysfunction are critical initiating events in the pathogenesis of atherosclerosis. Human studies have demonstrated that vitamin B6 deficiency affects cellular and humoral responses of the immune system. Vitamin B6 deficiency results in altered lymphocyte differentiation and maturation, reduced delayed-type hypersensitivity (DTH) responses, impaired antibody production, decreased lymphocyte proliferation and decreased interleukin (IL)-2 production, among other immunologic activities.
Riboflavin¿¡ ´ëÇÑ Pharmacology Á¤º¸ Riboflavin or vitamin B2 is an easily absorbed, water-soluble micronutrient with a key role in maintaining human health. Like the other B vitamins, it supports energy production by aiding in the metabolising of fats, carbohydrates, and proteins. Vitamin B2 is also required for red blood cell formation and respiration, antibody production, and for regulating human growth and reproduction. It is essential for healthy skin, nails, hair growth and general good health, including regulating thyroid activity. Riboflavin also helps in the prevention or treatment of many types of eye disorders, including some cases of cataracts.
Thiamine¿¡ ´ëÇÑ Pharmacology Á¤º¸ Thiamine is a vitamin with antioxidant, erythropoietic, cognition-and mood-modulatory, antiatherosclerotic, putative ergogenic, and detoxification activities. Thiamine has been found to protect against lead-induced lipid peroxidation in rat liver and kidney. Thiamine deficiency results in selective neuronal death in animal models. The neuronal death is associated with increased free radical production, suggesting that oxidative stress may play an important early role in brain damage associated with thiamine deficiency. Thiamine plays a key role in intracellular glucose metabolism and it is thought that thiamine inhibits the effect of glucose and insulin on arterial smooth muscle cell proliferation. Inhibition of endothelial cell proliferation may also promote atherosclerosis. Endothelial cells in culture have been found to have a decreased proliferative rate and delayed migration in response to hyperglycemic conditions. Thiamine has been shown to inhibit this effect of glucose on endothelial cells.
|
| Metabolism |
Cholecalciferol¿¡ ´ëÇÑ Metabolism Á¤º¸ # Phase_1_Metabolizing_Enzyme:Cytochrome P450 24A1 (CYP24A1)Cytochrome P450 11A1 (CYP11A1)
Pyridoxine¿¡ ´ëÇÑ Metabolism Á¤º¸ # Phase_1_Metabolizing_Enzyme:Methylenetetrahydrofolate reductase
Riboflavin¿¡ ´ëÇÑ Metabolism Á¤º¸ # Phase_1_Metabolizing_Enzyme:Monoamine oxidase type A (MAO-A)Methylenetetrahydrofolate reductase
|
| Absorption |
Cholecalciferol¿¡ ´ëÇÑ Absorption Á¤º¸ Readily absorbed
Pyridoxine¿¡ ´ëÇÑ Absorption Á¤º¸ The B vitamins are readily absorbed from the gastrointestinal tract, except in malabsorption syndromes. Pyridoxine is absorbed mainly in the jejunum.
Riboflavin¿¡ ´ëÇÑ Absorption Á¤º¸ Vitamin B2 is readily absorbed from the upper gastrointestinal tract.
Thiamine¿¡ ´ëÇÑ Absorption Á¤º¸ Absorbed mainly from duodenum, by both active and passive processes
|
| Toxicity |
Cholecalciferol¿¡ ´ëÇÑ Toxicity Á¤º¸ Hypercalcemia - Early symptoms of hypercalcemia, include nausea and vomiting, weakness, headache, somnolence, dry mouth, constipation, metallic taste, muscle pain and bone pain. Late symptoms and signs of hypercalcemia, include polyuria, polydipsia, anorexia, weight loss, nocturia, conjunctivitis, pancreatitis, photophobia, rhinorrhea, pruritis, hyperthermia, decreased libido, elevated BUN, albuminuria, hypercholesterolemia, elevated ALT (SGPT) and AST (SGOT), ectopic calcification, nephrocalcinosis, hypertension and cardiac arrhythmias.
Pyridoxine¿¡ ´ëÇÑ Toxicity Á¤º¸ Oral Rat LD50 = 4 gm/kg. Toxic effects include convulsions, dyspnea, hypermotility, diarrhea, ataxia and muscle weakness.
Riboflavin¿¡ ´ëÇÑ Toxicity Á¤º¸ Not Available
Thiamine¿¡ ´ëÇÑ Toxicity Á¤º¸ Thiamine toxicity is uncommon; as excesses are readily excreted, although long-term supplementation of amounts larger than 3 gram have been known to cause toxicity. Oral mouse LD50 = 8224 mg/kg, oral rat LD50 = 3710 mg/kg.
|
| Drug Interactions |
Cholecalciferol¿¡ ´ëÇÑ Drug_Interactions Á¤º¸ Not Available
Pyridoxine¿¡ ´ëÇÑ Drug_Interactions Á¤º¸ Not Available
Riboflavin¿¡ ´ëÇÑ Drug_Interactions Á¤º¸ Not Available
Thiamine¿¡ ´ëÇÑ Drug_Interactions Á¤º¸ Not Available
|
CYP450 Drug Interaction |
[CYP450 TableÁ÷Á¢Á¶È¸]
|
| Drug Target |
[Drug Target]
|
| Description |
Cholecalciferol¿¡ ´ëÇÑ Description Á¤º¸ Derivative of 7-dehydroxycholesterol formed by ultraviolet rays breaking of the C9-C10 bond. It differs from ergocalciferol in having a single bond between C22 and C23 and lacking a methyl group at C24. [PubChem]
Nicotinamide¿¡ ´ëÇÑ Description Á¤º¸ An important compound functioning as a component of the coenzyme NAD. Its primary significance is in the prevention and/or cure of blacktongue and pellagra. Most animals cannot manufacture this compound in amounts sufficient to prevent nutritional deficiency and it therefore must be supplemented through dietary intake. [PubChem]
Pyridoxine¿¡ ´ëÇÑ Description Á¤º¸ The 4-methanol form of vitamin B 6 which is converted to pyridoxal phosphate which is a coenzyme for synthesis of amino acids, neurotransmitters (serotonin, norepinephrine), sphingolipids, aminolevulinic acid. Although pyridoxine and Vitamin B 6 are still frequently used as synonyms, especially by medical researchers, this practice is erroneous and sometimes misleading (EE Snell; Ann NY Acad Sci, vol 585 pg 1, 1990). [PubChem]
Riboflavin¿¡ ´ëÇÑ Description Á¤º¸ Nutritional factor found in milk, eggs, malted barley, liver, kidney, heart, and leafy vegetables. The richest natural source is yeast. It occurs in the free form only in the retina of the eye, in whey, and in urine; its principal forms in tissues and cells are as flavin mononucleotide and flavin-adenine dinucleotide. [PubChem]
Thiamine¿¡ ´ëÇÑ Description Á¤º¸ 3-((4-Amino-2-methyl-5-pyrimidinyl)methyl)-5-(2- hydroxyethyl)-4-methylthiazolium chloride. [PubChem]
|
| Dosage Form |
Cholecalciferol¿¡ ´ëÇÑ Dosage_Form Á¤º¸ Capsule OralTablet Oral
Pyridoxine¿¡ ´ëÇÑ Dosage_Form Á¤º¸ Liquid IntramuscularSolution IntramuscularSolution / drops OralTablet Oral
Riboflavin¿¡ ´ëÇÑ Dosage_Form Á¤º¸ Not Available
Thiamine¿¡ ´ëÇÑ Dosage_Form Á¤º¸ Liquid IntramuscularLiquid IntravenousSolution IntravenousTablet Oral
|
| Drug Category |
Cholecalciferol¿¡ ´ëÇÑ Drug_Category Á¤º¸ Antihypocalcemic AgentsAntihypoparathyroid AgentsBone Density Conservation AgentsEssential VitaminVitaminsVitamins (Vitamin D)
Nicotinamide¿¡ ´ëÇÑ Drug_Category Á¤º¸ Vitamin B Complex
Pyridoxine¿¡ ´ëÇÑ Drug_Category Á¤º¸ Anti-inflammatory AgentsEssential VitaminVitamin B ComplexVitamins (Vitamin B Complex)
Riboflavin¿¡ ´ëÇÑ Drug_Category Á¤º¸ Photosensitizing AgentsRadiation-Sensitizing AgentsVitamin B ComplexVitamins (Vitamin B Complex)
Thiamine¿¡ ´ëÇÑ Drug_Category Á¤º¸ Anti-inflammatory AgentsEssential VitaminVitamin B ComplexVitamins (Vitamin B Complex)
|
| Smiles String Canonical |
Cholecalciferol¿¡ ´ëÇÑ Smiles_String_canonical Á¤º¸ CC(C)CCCC(C)C1CCC2C(CCCC12C)=CC=C1CC(O)CCC1=C
Nicotinamide¿¡ ´ëÇÑ Smiles_String_canonical Á¤º¸ NC(=O)C1=CC=CN=C1
Pyridoxine¿¡ ´ëÇÑ Smiles_String_canonical Á¤º¸ CC1=NC=C(CO)C(CO)=C1O
Riboflavin¿¡ ´ëÇÑ Smiles_String_canonical Á¤º¸ CC1=CC2=C(C=C1C)N(CC(O)C(O)C(O)CO)C1=NC(=O)NC(=O)C1=N2
Thiamine¿¡ ´ëÇÑ Smiles_String_canonical Á¤º¸ CC1=NC=C(C[N+]2=CSC(CCO)=C2C)C(N)=N1
|
| Smiles String Isomeric |
Cholecalciferol¿¡ ´ëÇÑ Smiles_String_isomeric Á¤º¸ CC(C)CCC[C@@H](C)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1\C[C@@H](O)CCC1=C
Nicotinamide¿¡ ´ëÇÑ Smiles_String_isomeric Á¤º¸ NC(=O)C1=CC=CN=C1
Pyridoxine¿¡ ´ëÇÑ Smiles_String_isomeric Á¤º¸ CC1=NC=C(CO)C(CO)=C1O
Riboflavin¿¡ ´ëÇÑ Smiles_String_isomeric Á¤º¸ CC1=CC2=C(C=C1C)N(C[C@@H](O)[C@@H](O)[C@@H](O)CO)C1=NC(=O)NC(=O)C1=N2
Thiamine¿¡ ´ëÇÑ Smiles_String_isomeric Á¤º¸ CC1=NC=C(C[N+]2=CSC(CCO)=C2C)C(N)=N1
|
| InChI Identifier |
Cholecalciferol¿¡ ´ëÇÑ InChI_Identifier Á¤º¸ InChI=1/C27H44O/c1-19(2)8-6-9-21(4)25-15-16-26-22(10-7-17-27(25,26)5)12-13-23-18-24(28)14-11-20(23)3/h12-13,19,21,24-26,28H,3,6-11,14-18H2,1-2,4-5H3/t21-,24+,25-,26+,27-/m1/s1
Nicotinamide¿¡ ´ëÇÑ InChI_Identifier Á¤º¸ InChI=1/C6H6N2O/c7-6(9)5-2-1-3-8-4-5/h1-4H,(H2,7,9)/f/h7H2
Pyridoxine¿¡ ´ëÇÑ InChI_Identifier Á¤º¸ InChI=1/C8H11NO3/c1-5-8(12)7(4-11)6(3-10)2-9-5/h2,10-12H,3-4H2,1H3
Riboflavin¿¡ ´ëÇÑ InChI_Identifier Á¤º¸ InChI=1/C17H20N4O6/c1-7-3-9-10(4-8(7)2)21(5-11(23)14(25)12(24)6-22)15-13(18-9)16(26)20-17(27)19-15/h3-4,11-12,14,22-25H,5-6H2,1-2H3,(H,20,26,27)/t11-,12+,14-/m1/s1/f/h20H
Thiamine¿¡ ´ëÇÑ InChI_Identifier Á¤º¸ InChI=1/C12H17N4OS/c1-8-11(3-4-17)18-7-16(8)6-10-5-14-9(2)15-12(10)13/h5,7,17H,3-4,6H2,1-2H3,(H2,13,14,15)/q+1/f/h13H2
|
| Chemical IUPAC Name |
Cholecalciferol¿¡ ´ëÇÑ Chemical_IUPAC_Name Á¤º¸ (1S)-3-[2-[(1R,3aS,7aR)-7a-methyl-1-[(2R)-6-methylheptan-2-yl]-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexan-1-ol
Nicotinamide¿¡ ´ëÇÑ Chemical_IUPAC_Name Á¤º¸ pyridine-3-carboxamide
Pyridoxine¿¡ ´ëÇÑ Chemical_IUPAC_Name Á¤º¸ 4,5-bis(hydroxymethyl)-2-methylpyridin-3-ol
Riboflavin¿¡ ´ëÇÑ Chemical_IUPAC_Name Á¤º¸ 7,8-dimethyl-10-[(2R,3R,4S)-2,3,4,5-tetrahydroxypentyl]benzo[g]pteridine-2,4-dione
Thiamine¿¡ ´ëÇÑ Chemical_IUPAC_Name Á¤º¸ 2-[3-[(4-amino-2-methylpyrimidin-5-yl)methyl]-4-methyl-1,3-thiazol-3-ium-5-yl]ethanol
|
| Drug-Induced Toxicity Related Proteins |
VITAMIN A ÀÇ Drug-Induced Toxicity Related ProteinÁ¤º¸ Replated Protein:Retinol-binding protein, cellular Drug:vitamin a Toxicity:acute inflammation . [¹Ù·Î°¡±â] Replated Protein:Retinol-binding protein (RBP) Drug:vitamin a Toxicity:renal osteodystrophy. [¹Ù·Î°¡±â]
|
|
|
 | »ç¿ëÀÚÄÁÅÙÃ÷ |
|
|
|
|
|
-
ÃÖ±ÙÁ¤º¸¼öÁ¤ÀÏ 2022-07-05
-
º» ¼öÁ¤ÀÏ Á¤º¸´Â Çã°¡Á¤º¸ ÀÌ¿ÜÀÇ ±âŸÁ¤º¸ ¼öÁ¤ÀÏÀ» ÀǹÌÇϹǷÎ, Çã°¡Á¤º¸¼öÁ¤ÀÏÀº º»¹®¿¡ Ç¥±âµÈ ³¯Â¥¸¦ ÂüÁ¶ÇϽñ⠹ٶø´Ï´Ù.
|
|
¾Ë¸² |
»ó¼¼Á¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×À» Åä´ë·Î ÀÛ¼ºµÇ¾úÀ¸¸ç ¿ä¾àÁ¤º¸´Â »ó¼¼Á¤º¸ ¹× ±âŸ¹®ÇåÀ» ±â¹ÝÀ¸·Î µå·°ÀÎÆ÷¿¡¼ ÆíÁýÇÑ ³»¿ëÀÔ´Ï´Ù. Á¦Ç°Çã°¡»çÇ×ÀÇ ¸ñÂ÷¿Í ´Ù¼Ò »óÀÌÇÒ ¼ö ÀÖ½À´Ï´Ù. |
|
°æ°í |
µå·°ÀÎÆ÷ ÀǾàÇмúÁ¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×, Çмú¹®Çå, Á¦¾àȸ»ç Á¦°øÁ¤º¸ µîÀ» ±Ù°Å·Î ÀÛ¼ºµÈ Âü°í Á¤º¸ÀÔ´Ï´Ù.
Á¤º¸ÀÇ Á¤È®¼ºÀ» À§ÇØ ³ë·ÂÇϰí ÀÖÀ¸³ª ÆíÁý»óÀÇ ¿À·ù, Çã°¡»çÇ× º¯°æ, Ãß°¡ÀûÀÎ Çмú¿¬±¸ ¶Ç´Â Àӻ󿬱¸ ¹ßÇ¥ µîÀ¸·Î ÀÎÇØ ¹ß»ýÇÏ´Â ¹®Á¦¿¡ ´ëÇØ µå·°ÀÎÆ÷´Â
Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù. ÀÚ¼¼ÇÑ ³»¿ëÀº ¡°Ã¥ÀÓÀÇ ÇÑ°è ¹× ¹ýÀû°íÁö¡±¸¦ ÂüÁ¶ÇØ ÁֽʽÿÀ.
¹Ýµå½Ã Á¦Á¶¡¤¼öÀÔ»ç, ÆÇ¸Å»ç, ÀÇ»ç, ¾à»ç¿¡°Ô ÃÖÁ¾ÀûÀ¸·Î È®ÀÎÇϽñ⠹ٶø´Ï´Ù.
ÀüÈ: 02-3486-1061 ¤Ó À̸ÞÀÏ: webmaster@druginfo.co.kr
|
|
¾Æ·¡ÀÇ ³»¿ëÀ» Æ÷ÇÔÇÑ Àüü µ¥ÀÌÅ͸¦ º¸½Ã·Á¸é
¿©±â·Î À̵¿ÇϽñ⠹ٶø´Ï´Ù.
º´¿ë±Ý±â ¹× ƯÁ¤¿¬·É´ë ±Ý±â ¼ººÐ
|